Philogen S.p.A.
48
8
12
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
22.9%
11 terminated/withdrawn out of 48 trials
57.7%
-28.8% vs industry average
6%
3 trials in Phase 3/4
0%
0 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (48)
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
Role: lead
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Role: lead
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Role: lead
L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma
Role: lead
L19IL2/TNF in Patients With Basal Cell Carcinoma
Role: lead
Safety and Early Signs of Efficacy of IL12-L19L19.
Role: lead
A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors
Role: lead
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer
Role: lead
A Study of F8IL10 Intra-articular Treatment in Rheumatoid Arthritis
Role: lead
A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
Role: lead
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Role: lead
Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular Treatment
Role: lead
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Role: lead
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Role: lead
A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors
Role: lead
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Role: lead
Neoadjuvant L19IL2/L19TNF- Pivotal Study
Role: lead
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
Role: lead
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Role: lead
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Role: lead